CFO Christina Rubenhag will leave Boule in June, 2022
Boule Diagnostics AB’s CFO Christina Rubenhag has decided to leave her position and assume the position of CFO at AddLife.
Christina has had her position since 2017 and will continue in this capacity during her six-month notice period in order to ensure an orderly transition period up until a new CFO assumes the position. The process of recruiting a new CFO will begin immediately.
”Christina has played a key part in the Company and has been of great importance in our strategic development including market expansion and the upgraded product portfolio as well as in her work to modernize our internal governance, processes and tools in order to increase our internal efficiency. Christina was also the interim CEO in the beginning of 2020. I would like to thank her for her time and efforts at Boule and wish her all best with her future endeavors.” says CEO and Group President, Jesper Söderqvist.
For more information, please contact: Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 (0)70-546 72 22
About Boule Diagnostics AB (publ) Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com
This information is information that Boule Diagnostics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of the contact person set out above, at 16:30 CET on December 9, 2021.